| 2018-06-15 |
2-Aroylquinoline-5,8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (HSP90) inhibition [Erratum: Organic and Biomolecular Chemistry. 2016 Jan;14(2):716-723.] |
Organic and biomolecular chemistry. 2018 Jun 15;16:4734. |
 |
| 2018-04 |
4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy |
Bioorganic Chemistry. 2018 Apr;77:600-607. |
|
| 2018-02-08 |
Development of stem-cell-mobilizing agents targeting CXCR4 receptor for peripheral blood stem cell transplantation and beyond |
Journal of Medicinal Chemistry. 2018 Feb 8;61(3):818-833. |
|
| 2018-01-01 |
Identification of an oxime-containing C-glucosylarene as a potential inhibitor of sodium-dependent glucose co-transporter 2 |
European Journal of Medicinal Chemistry. 2018 Jan 1;143:611-620. |
|
| 2018-01 |
Discovery and development of DBPR112 as a clinical candidate: A novel EGFR inhibitor for non-small cell lung cancer |
Cancer Science. 2018 Jan;109(Suppl. 1):739. |
|
| 2017-08-11 |
Targeting P-glycoprotein: Investigation of piperine analogs for overcoming drug resistance in cancer |
Scientific Reports. 2017 Aug 11;7:Article number 7972. |
|
| 2017-07 |
Design, synthesis, and evaluation of thiazolidine-2,4-dione derivatives as a novel class of glutaminase inhibitors |
Journal of Medicinal Chemistry. 2017 Jul;60(13):5599-5612. |
|
| 2017-07 |
Targeting tumor associated phosphatidylserine with new zinc dipicolylamine-based drug conjugates |
Bioconjugate Chemistry. 2017 Jul;28(7):1878-1892. |
|
| 2017-05 |
1-(2,4-Dibromophenyl)-3,6,6-trimethyl-1,5,6,7-tetrahydro-4H-indazol-4-one: A novel opioid receptor agonist with less accompanying gastrointestinal dysfunction than morphine |
Anesthesiology. 2017 May;126(5):952-966. |
|
| 2017-04 |
Discovery of BPR1K871-a quinazoline based multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation |
Abstracts of Papers of the American Chemical Society. 2017 Apr;253:Meeting Abstract 482. |
|
| 2017-01 |
Discovery, structure-activity relationship studies, and anti-nociceptive effects of N-(1,2,3,4-tetrahydro-1-isoquinolinylmethyl)benzamides as novel opioid receptor agonists |
European Journal of Medicinal Chemistry. 2017 Jan;126:202-217. |
|
| 2017-01 |
A potent, selective, and orally bioavailable HCV NS5A inhibitor for treatment of Hepatitis C Virus: (S)-1-((R)-2-(Cyclopropanecarboxamido)-2-phenylacetyl)-N-(4-phenylthiazo l-2-yl)pyrrolidine-2-carboxamide |
Journal of Medicinal Chemistry. 2017 Jan;60(1):228-247. |
|
| 2016-12-08 |
Bromomethylthioindole inspired carbazole hybrids as promising class of anti-MRSA agents |
ACS Medicinal Chemistry Letters. 2016 Dec 8;7(12):1191-1196. |
|
| 2016-12 |
Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation |
Oncotarget. 2016 Dec;7(52):86239-86256. |
|
| 2016-12 |
Phenyl benzenesulfonylhydrazides: Selective indoleamine 2,3-dioxygenase inhibitors with potent in vivo pharmacodynamic activity and antitumor efficacy |
European Journal of Cancer. 2016 Dec;68(Suppl. 1):S83-S84. |
|
| 2016-12 |
Novel cKIT kinase inhibitor, BPRCKJ001, as an advanced therapeutic candidate for GIST |
Annals of Oncology. 2016 Dec;27(Suppl. 9):Meeting Abstract 2P. |
|
| 2016-09 |
Activation of delta-opioid receptor contributes to the antinociceptive effect of oxycodone in mice |
Pharmacological Research. 2016 Sep;111:867-876. |
|
| 2016-07 |
In vitro and in vivo studies of a potent capsid-binding inhibitor of enterovirus 71 |
Journal of Antimicrobial Chemotherapy. 2016 Jul;71(7):1922-1932. |
|
| 2016-05 |
N-Indolylglycosides bearing modifications at the glucose C6-Position as Sodium-Dependent Glucose Co-transporter 2 inhibitors |
Bioorganic and Medicinal Chemistry. 2016 May;24(10):2242-2250. |
|
| 2016-01 |
2-Aroylquinoline-5,8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (HSP90) inhibition |
Organic and Biomolecular Chemistry. 2016 Jan;14(2):716-723. |
|
| 2016-01 |
Phenyl benzenesulfonylhydrazides exhibit selective Indoleamine 2,3-Dioxygenase inhibition with potent in vivo pharmacodynamic activity and antitumor efficacy |
Journal of Medicinal Chemistry. 2016 Jan;59(1):419-430. |
|
| 2015-10 |
Identification of substituted naphthotriazolediones as novel tryptophan 2,3-dioxygenase (TDO) inhibitors through structure-based virtual screening |
Journal of Medicinal Chemistry. 2015 Oct;58 (19):7807-7819. |
|
| 2015-08 |
Novel Nrf2/ARE activator, trans-coniferylaldehyde, induces a HO-1-mediated defense mechanism through a dual p38alpha/MAPKAPK-2 and PK-N3 signaling pathway |
Chemical Research in Toxicology. 2015 Aug ;28(9):1681-1692. |
|
| 2015-08 |
Zinc-dipicolylamine directed pharmaceutical delivery system (ZAPS) as an innovative cancer drug delivery platform |
Cancer Research. 2015 Aug;75(Suppl. 15):Abstract number 4413. |
|
| 2015-08 |
Optimization of quinazoline-based kinase inhibitors: Identification of a dual FLT3/AURKA kinase inhibitor for the treatment of acute myeloid leukemia |
Abstracts of Papers of the American Chemical Society. 2015 Aug;250:Meeting Abstract 490. |
|
| 2015-07 |
Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations |
European Journal of Medicinal Chemistry. 2015 Jul;100:151-161. |
|
| 2015-01 |
1-Arylsulfonyl-5-(N-hydroxyacrylamide)tetrahydroquinolines as potent histone deacetylase inhibitors suppressing the growth of prostate cancer cells |
European Journal of Medicinal Chemistry. 2015 Jan;89:320-330. |
|
| 2014-11-19 |
咪唑-4-酮及咪唑-4-硫酮化合物 |
CN101723937/2014-11-19 |
|
| 2014-11 |
Discovery of multiple kinases inhibitors, DBPR114, as the novel anti-cancer agent |
European Journal of Cancer. 2014 Nov;50(Suppl. 6):92-93. |
|
| 2014-10 |
Novel irreversible EGFR tyrosine kinase inhibitor, DBPR112, as a therapeutic candidate for lung adenocarcinoma |
Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 1756. |
|
| 2014-08-15 |
Anticancer oral formulation |
JP5596680/2014-08-15 |
|
| 2014-06-04 |
抗癌口服制剂 |
CN102159541/2014-06-04 |
|
| 2014-05 |
Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells |
Journal of Medicinal Chemistry. 2014 May;57(10):4009-4022. |
|
| 2014-04-21 |
咪唑-4-酮及咪唑-4-硫酮化合物 |
TWI434686/2014-04-21 |
|
| 2014-04 |
Antimitotic and vascular disrupting agents: 2-hydroxy-3,4,5-trimethoxybenzophenones |
European Journal of Medicinal Chemistry. 2014 Apr 22;77(2):306-314. |
|
| 2014-03 |
DBPR112, a potent and selective EGFR kinase inhibitor in preclinical study |
Abstracts of Papers - American Chemical Society. 2014 Mar;247:Article number 315-MEDI. |
|
| 2014-01-08 |
Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer |
PLoS ONE. 2014 Jan 8;9(1):Article number e83160. |
|
| 2013-11-13 |
Discovery of 1-(2,4-Dichlorophenyl)-N-(piperidin-1-yl)-4-((pyrrolidine-1-sulfonamido)methyl)-5 -(5-((4-(trifluoromethyl)phenyl)ethynyl)thiophene-2-yl)-1H-pyrazole-3-carboxamide as a novel peripherally restricted cannabinoid-1 receptor antagonist with significant weight-loss efficacy in diet-induced obese mice |
Journal of Medicinal Chemistry. 2013 Nov 13;56(24):9920-9933. |
|
| 2013-11 |
BPR0C305, an orally active microtubule-disrupting anticancer agent |
Anticancer Drugs. 2013 Nov;24(10):1047-1057. |
|
| 2013-11 |
A development drug candidate targeting EGFR kinase for lung cancer: DBPR112 |
Journal of Thoracic Oncology. 2013 Nov;8(Suppl. 2):S779-S780. |
|
| 2013-07-08 |
1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines histone deacetylase inhibitors are potent cytokine release suppressors |
ChemBioChem. 2013 Jul 8;14(10):1248-1254. |
|
| 2013-07-08 |
Inside Cover: 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines histone deacetylase inhibitors are potent cytokine release suppressors(ChemBioChem 10/2013) |
ChemBioChem. 2013 Jul 8;14(10):1150. |
|
| 2013-07 |
CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions |
Pharmacogenomics. 2013 Jul;14(10):1191-1201. |
|
| 2013-06-05 |
Anticancer oral formulation |
EP2310363/2013-06-05 |
|
| 2013-06 |
Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3) |
Bioorganic and Medicinal Chemistry. 2013 Jun;21(11):2856-2867. |
|
| 2013-04-13 |
Exploration of the role of tylophorine E ring in anti-Coronavirus activity-Tylophorine derived dibenzoquinolines impart multi-biological activities as orally active agents |
FASEB Journal. 2013 Apr 13;27:lb71. |
|
| 2013-04-07 |
BPR000K, a novel Aurora kinase inhibitor |
Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 300-MEDI. |
|
| 2013-04-07 |
3D-QSAR assisted drug design: Identification of a potent quinazoline based Aurora kinase inhibitor |
Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 87-MEDI. |
|
| 2013-04-07 |
Development drug candidate targeting EGFR kinase: DBPR112 |
Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 299-MEDI. |
|
| 2013-02-11 |
抗癌口服藥學組成物 |
TWI384984/2013-02-11 |
|
